1. Song TJ, Cho SJ, Kim WJ, Yang KI, Yun CH, Chu MK. Sex differences in prevalence, symptoms, impact, and psychiatric comorbidities in migraine and probable migraine: a population-based study. Headache 2019;59:215-223.
3. Korean Headache Society. Korean version of the international classification of headache disorders. 3rd ed. Seoul: Korean Headache Society; 2018.
4. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF; AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-349.
5. Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA, Wilcox TK, Kawata AK, Lipton RB. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache 2013;53:644-655.
6. American Headache Society. The American Headache Society Position Statement On integrating new migraine treatments into clinical practice. Headache 2019;59:1-18.
7. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF; PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30:793-803.
8. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF; PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30:804-814.
9. Goadsby PJ, Reuter U, Hallstrom Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA. A controlled trial of erenumab for episodic migraine. N Engl J Med 2017;377:2123-2132.
10. Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 2018;319:1999-2008.
12. Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Smith J. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 2020;40:241-254.
13. Korean Headache Society. Treatment guideline of pharmacological preventive therapy for episodic migraine. Seoul: Medical Publisher Co; 2019.
14. Torres-Ferrus M, Quintana M, Fernandez-Morales J, AlvarezSabin J, Pozo-Rosich P. When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month Cephalalgia 2017;37:104-113.
16. Cha MJ, Kim BS, Cho SJ. Headache education and assessment for migraineurs. J Korean Neurol Assoc 2020;38:169-174.
17. Chu MK, Im HJ, Ju YS, Yu KH, Ma HI, Kim YJ, Kim J, Lee BC. Validity and reliability assessment of Korean headache impact test-6 (HIT-6). J Korean Neurol Assoc 2009;27:1-6.
18. Lee HS, Chung CS, Song HJ, Park HS. The reliability and validity of the midas (migraine disability assessment) questionnaire for Korean migraine sufferers. J Korean Neurol Assoc 2000;18:287-291.
19. Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ; International Headache Society Clinical Trials Standing Committee. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia 2018;38:815-832.
21. Pringsheim T, Davenport W, Mackie G, Worthington I, Aube M, Christie SN, Gladstone J, Becker WJ; Canadian Headache Society Prophylactic Guidelines Development Group. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci 2012;39((2 Suppl 2):S1-S59.
22. Moon HS, Park KY, Chung JM, Kim BK. An update on migraine treatment. J Korean Neurol Assoc 2020;38:100-110.
24. Park HK, Kim BK. Calcitonin gene-related peptide targeting therapies for migraine: a new era for migraine treatment. J Korean Neurol Assoc 2020;38:88-99.